(EMR) Emerson Electric - Overview
Stock: Valves, Analyzers, Automation, Software, Tools
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.71% |
| Yield on Cost 5y | 2.77% |
| Yield CAGR 5y | 1.30% |
| Payout Consistency | 100.0% |
| Payout Ratio | 35.6% |
| Risk 5d forecast | |
|---|---|
| Volatility | 28.1% |
| Relative Tail Risk | -6.23% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.89 |
| Alpha | 8.81 |
| Character TTM | |
|---|---|
| Beta | 1.260 |
| Beta Downside | 1.380 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.62% |
| CAGR/Max DD | 0.85 |
Description: EMR Emerson Electric January 27, 2026
Emerson Electric Co. (NYSE: EMR) is a diversified technology and software firm that serves process, industrial, and consumer markets worldwide through six operating segments: Final Control (valves, actuators, regulators), Measurement & Analytical (pressure, temperature, flow and gas sensors), Discrete Automation (solenoid/pneumatic valves, motion solutions, automation software), Safety & Productivity (hand and power tools for professionals and DIY users), Control Systems & Software (DeltaV and Ovation platforms that integrate plant data), and Test & Measurement (automated test equipment). The company, founded in 1890 and based in St. Louis, Missouri, markets its products under brands such as Anderson-Greenwood, Rosemount, ASCO, Greenlee, and RIDGID.
In its most recent fiscal year (FY 2025), Emerson reported revenue of roughly $19.1 billion, a 4.2 % increase YoY, driven primarily by a 7 % rise in Final Control sales and a 5 % boost in Measurement & Analytical shipments. Operating margin expanded to 13.5 % as cost-saving initiatives offset modest softening in oil-and-gas capex, which fell about 5 % year-over-year. A key sector driver remains the accelerating demand for automation in renewable-energy projects, where capital spending is up ~12 % and is expected to lift discrete-automation and control-systems sales over the next 12-24 months. The Safety & Productivity segment continues to benefit from a robust DIY market, with U.S. home-improvement spending projected to grow 3-4 % annually through 2027.
For a deeper dive into Emerson’s valuation metrics, you might explore the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 2.31b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -1.53 > 1.0 |
| NWC/Revenue: -9.22% < 20% (prev 18.44%; Δ -27.66% < -1%) |
| CFO/TA 0.07 > 3% & CFO 3.02b > Net Income 2.31b |
| Net Debt (12.17b) to EBITDA (4.99b): 2.44 < 3 |
| Current Ratio: 0.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (564.1m) vs 12m ago -1.23% < -2% |
| Gross Margin: 51.66% > 18% (prev 0.52%; Δ 5113 % > 0.5%) |
| Asset Turnover: 43.02% > 50% (prev 41.19%; Δ 1.83% > 0%) |
| Interest Coverage Ratio: 7.38 > 6 (EBITDA TTM 4.99b / Interest Expense TTM 450.0m) |
Altman Z'' 5.41
| A: -0.04 (Total Current Assets 8.84b - Total Current Liabilities 10.52b) / Total Assets 41.94b |
| B: 0.97 (Retained Earnings 40.87b / Total Assets 41.94b) |
| C: 0.08 (EBIT TTM 3.32b / Avg Total Assets 42.27b) |
| D: 1.87 (Book Value of Equity 40.52b / Total Liabilities 21.65b) |
| Altman-Z'' Score: 5.41 = AAA |
Beneish M -2.95
| DSRI: 1.06 (Receivables 2.97b/2.69b, Revenue 18.18b/17.55b) |
| GMI: 1.02 (GM 51.66% / 52.44%) |
| AQI: 1.00 (AQ_t 0.72 / AQ_t-1 0.72) |
| SGI: 1.04 (Revenue 18.18b / 17.55b) |
| TATA: -0.02 (NI 2.31b - CFO 3.02b) / TA 41.94b) |
| Beneish M-Score: -2.95 (Cap -4..+1) = A |
What is the price of EMR shares?
Over the past week, the price has changed by +7.66%, over one month by +10.96%, over three months by +23.63% and over the past year by +28.39%.
Is EMR a buy, sell or hold?
- StrongBuy: 19
- Buy: 3
- Hold: 6
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the EMR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 164.5 | 2.8% |
| Analysts Target Price | 164.5 | 2.8% |
| ValueRay Target Price | 194.6 | 21.6% |
EMR Fundamental Data Overview February 08, 2026
P/E Forward = 23.2019
P/S = 4.8658
P/B = 4.1835
P/EG = 1.9351
Revenue TTM = 18.18b USD
EBIT TTM = 3.32b USD
EBITDA TTM = 4.99b USD
Long Term Debt = 7.58b USD (from longTermDebt, last quarter)
Short Term Debt = 5.83b USD (from shortTermDebt, last quarter)
Debt = 13.92b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.17b USD (from netDebt column, last quarter)
Enterprise Value = 100.67b USD (88.50b + Debt 13.92b - CCE 1.75b)
Interest Coverage Ratio = 7.38 (Ebit TTM 3.32b / Interest Expense TTM 450.0m)
EV/FCF = 39.09x (Enterprise Value 100.67b / FCF TTM 2.58b)
FCF Yield = 2.56% (FCF TTM 2.58b / Enterprise Value 100.67b)
FCF Margin = 14.16% (FCF TTM 2.58b / Revenue TTM 18.18b)
Net Margin = 12.72% (Net Income TTM 2.31b / Revenue TTM 18.18b)
Gross Margin = 51.66% ((Revenue TTM 18.18b - Cost of Revenue TTM 8.79b) / Revenue TTM)
Gross Margin QoQ = 48.56% (prev 51.91%)
Tobins Q-Ratio = 2.40 (Enterprise Value 100.67b / Total Assets 41.94b)
Interest Expense / Debt = 0.83% (Interest Expense 116.0m / Debt 13.92b)
Taxrate = 21.81% (169.0m / 775.0m)
NOPAT = 2.60b (EBIT 3.32b * (1 - 21.81%))
Current Ratio = 0.84 (Total Current Assets 8.84b / Total Current Liabilities 10.52b)
Debt / Equity = 0.69 (Debt 13.92b / totalStockholderEquity, last quarter 20.29b)
Debt / EBITDA = 2.44 (Net Debt 12.17b / EBITDA 4.99b)
Debt / FCF = 4.73 (Net Debt 12.17b / FCF TTM 2.58b)
Total Stockholder Equity = 19.92b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.47% (Net Income 2.31b / Total Assets 41.94b)
RoE = 11.61% (Net Income TTM 2.31b / Total Stockholder Equity 19.92b)
RoCE = 12.08% (EBIT 3.32b / Capital Employed (Equity 19.92b + L.T.Debt 7.58b))
RoIC = 7.73% (NOPAT 2.60b / Invested Capital 33.63b)
WACC = 9.21% (E(88.50b)/V(102.42b) * Re(10.56%) + D(13.92b)/V(102.42b) * Rd(0.83%) * (1-Tc(0.22)))
Discount Rate = 10.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.81%
[DCF Debug] Terminal Value 72.10% ; FCFF base≈2.85b ; Y1≈2.60b ; Y5≈2.28b
Fair Price DCF = 37.34 (EV 33.16b - Net Debt 12.17b = Equity 20.99b / Shares 562.0m; r=9.21% [WACC]; 5y FCF grow -11.16% → 2.90% )
EPS Correlation: 50.03 | EPS CAGR: 3.36% | SUE: 0.78 | # QB: 0
Revenue Correlation: 58.58 | Revenue CAGR: 7.69% | SUE: -0.04 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.55 | Chg30d=-0.018 | Revisions Net=+2 | Analysts=21
EPS current Year (2026-09-30): EPS=6.52 | Chg30d=+0.056 | Revisions Net=+4 | Growth EPS=+8.7% | Growth Revenue=+5.3%
EPS next Year (2027-09-30): EPS=7.17 | Chg30d=+0.065 | Revisions Net=+3 | Growth EPS=+9.8% | Growth Revenue=+5.3%